Culture Medium for Ex Vivo Hematopoietic Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for the expansion and long-term maintenance of human erythroblast, megakaryocyte-erythroid progenitor, and common myeloid progenitor cells ex vivo are limited in capacity and effectiveness, hindering their clinical applications.
Innovation Solution
A culture medium comprising a tankyrase inhibitor, a B-Raf kinase inhibitor, and a GSK-3 inhibitor, along with a growth factor like stem cell factor, supports the long-term expansion and maintenance of these cells, allowing for significant expansion and differentiation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional culture methods with multiple growth factors are used, then cell expansion is attempted, but the expansion capacity is limited and long-term maintenance is not achieved
Solution Approach 1:
The patent changes the chemical parameters of the culture medium by incorporating specific inhibitors (tankyrase inhibitor, B-Raf kinase inhibitor, GSK-3 inhibitor) at optimized concentrations. This parameter modification enables both high expansion capacity (50-10,000 folds) and long-term maintenance (over 2 weeks), resolving the contradiction between expansion productivity and maintenance duration that plagues conventional methods.
2Productivity
If multiple growth factors are combined for cell expansion, then some expansion is achieved, but the method complexity increases and effectiveness remains limited
Solution Approach 1:
The patent extracts and isolates the key functional components needed for cell expansion by using specific inhibitors (tankyrase inhibitor, B-Raf kinase inhibitor, GSK-3 inhibitor) instead of complex combinations of multiple growth factors. This extraction approach simplifies the culture medium composition while maintaining or improving expansion efficiency, directly addressing the contradiction between productivity and complexity.
3Quantity of substance
If cells are expanded ex vivo, then cell quantity increases, but morphological integrity and differentiation capacity may be compromised
Solution Approach 1:
The patent applies prior cushioning by pre-treating cells with a carefully formulated culture medium containing specific inhibitors before expansion. This protective measure ensures that even as cell quantity increases dramatically (50-10,000 folds), the cells maintain their morphological integrity and differentiation capacity, preventing the degradation that typically occurs during ex vivo expansion.
Data Source
AI summary
The invention relates to a method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast, a human megakaryocyte-erythroid progenitor, or a human common myeloid progenitor, comprising the step of: culturing cells comprising one or more of those cells in a culture medium comprising one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor.